The Crohn's and Colitis Foundation of America has a good read/watch on lymphoma risks of biologics.
Webcast:
programs.rmei.com/CCFA139VL/presentation/player.htmlTranscript
: http://www.ccfa.org/assets/pdfs/risk-and-benefits-transcript
.pdf
The odds are 0.06% versus 0.02% for tge general population assuming he's using combination therapy of an Immunomodulator (imuran/azathioprine or 6mp) with the remicade. A lot of the newer research places the lymphoma blame strictly on the immunomodulators, as the initial remicade studies had zero instances of remicade-only patients getting a lymphoma (only immunomodulators plus remicade simultaneously patients).